The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...
A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for ...
Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic ...
Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...
Schmid detailed the rationale of combining pumitamig and chemotherapy and how the combination can aid patients in the first ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...
PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...
Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia ...
The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...
During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...
Erika Mayer, MD, MPH, Dana-Farber Cancer Institute, discusses the exciting findings of the phase 3 lidERA study investigating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback